Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 8921528 Bispecific fusion antibodies with enhanced serum half-life

Patent 8921528 was granted and assigned to Domantis Limited on December, 2014 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Current Assignee

‌

Domantis Limited

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

89215280

Patent Inventor Names

Lucy J. Holt0

Ian M. Tomlinson0

Date of Patent

December 30, 2014

Patent Application Number

116281490

Date Filed

May 31, 2005

Patent Citations Received

‌

US Patent 11859001 IL12RB1-Binding molecules and methods of use

‌

US Patent 11873349 Compositions and methods related to IL27 receptor binding

‌

US Patent 12006361 Albumin binding domain fusion proteins

‌

US Patent 12018085 Interferon-gamma R2 (IFNGR2) binding molecules comprising single-domain antibodies and method of use thereof to treat autoimmune and inflammatory diseases

‌

US Patent 12012457 IL23R binding molecules and methods of use

‌

US Patent 12077594 IL2RG binding molecules and methods of use

‌

US Patent 12134635 Interleukin 18 (IL-18) variants and fusion proteins comprising same

‌

US Patent 12122839 IFNGR binding synthetic cytokines and methods of use

...

Patent Primary Examiner

‌

Phuong Huynh

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 8921528 Bispecific fusion antibodies with enhanced serum half-life

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API